Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...

Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

Biopharmaceutical company Gilead Sciences has hired Bob Allen as head of omnichannel strategy and digital transformation for public affairs.

Perettie’s confidence stems from data shared at ASH on Dec. 6, when Kite revealed that patients treated with the Arcellx-partnered autologous therapy achieved a 96% overall response rate at the 15.9 ...

After a yearslong court battle against a network of alleged HIV drug fraudsters, Gilead Sciences has emerged victorious with $175.2 million in judgments. Gilead has traveled a long road since the ...

Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for HIV prevention to Eswatini and Zambia, marking a significant ...

The stock's rise snapped a four-day losing streak.